Trial watch: personalized medicines in late-stage development.
Tufts University at the time of this study, working under the aegis of the Tufts Center for the Study of Drug Development, Tufts University Medical School, 75 Kneeland St, Suite 1100, Boston, Massachusetts 02111, USA.
Christopher-Paul
CP
Milne
Tufts University at the time of this study, working under the aegis of the Tufts Center for the Study of Drug Development, Tufts University Medical School, 75 Kneeland St, Suite 1100, Boston, Massachusetts 02111, USA.
Steve
S
Garafalo
Tufts University at the time of this study, working under the aegis of the Tufts Center for the Study of Drug Development, Tufts University Medical School, 75 Kneeland St, Suite 1100, Boston, Massachusetts 02111, USA.
Crystal
C
Bryan
Tufts University at the time of this study, working under the aegis of the Tufts Center for the Study of Drug Development, Tufts University Medical School, 75 Kneeland St, Suite 1100, Boston, Massachusetts 02111, USA.
Marie
M
McKiernan
D017322:Clinical Trials, Phase II as Topic / Q000379:methods* / Q000639:trends; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D004345:Drug Industry / Q000379:methods* / Q000639:trends; D006801:Humans; D057285:Precision Medicine / Q000379:methods* / Q000639:trends